Low serum XXXX as a poor prognostic indicator for mortality in @entity712 @entity1 .

@entity1 @entity712 @entity1372 @entity2753
BACKGROUND: The incidence of @entity712 ( @entity712 ) has not significantly declined over the past 50 years, and overall survival rates are low at 5 years following diagnosis. Numerous studies have shown low serum @entity1372 to be a poor prognostic indicator of all cause mortality in @entity712 @entity1 . HYPOTHESIS: The goal of this hypothesis was to validate if @entity2753 is an important predictor of mortality in an outpatient population of @entity712 @entity1 on maximal combined angiotensin-converting enzyme inhibitor (ACEI) and b-blocker therapy. METHODS: A total of 364 (13% with @entity2753 ) @entity1 with @entity712 (ejection fraction [EF]  <= 40%) were enrolled in a @entity712 disease management program. The mean New York Heart Association (NYHA) class was II.XII. The average baseline serum @entity1372 was 138.2 mEq/L. RESULTS: We evaluated the relationship between @entity2753 (<135 mEq/L) and all-cause mortality at 40 months. During follow-up, 8 @entity1 in the @entity2753 group compared to 31 in the normonatremic group died. Results of Kaplan-Meier analyses indicated there were no significant differences in mortality between the @entity2753 and normonatremic groups (log-rank test = 0.39). Results for Cox proportional hazards models indicated low @entity1372 was not a significant predictor of mortality (unadjusted odds ratio [OR]: 1.41, 95% confidence interval [CI]: 0.65, 3.07; adjusted OR: 1.60, 95% CI: 0.57, 4.53). CONCLUSIONS: The relationship between @entity2753 and all-cause mortality did not reach significance. @entity2753 did not significantly predict mortality in a @entity712 population on maximal medical therapy. Copyright    2010 Wiley Periodicals, Inc.
